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Breast cancer prognosis has improved greatly in recent years. Consequently, a thorough search for sensitive prognostic
factors, able to help clinicians offer appropriate therapy, has become a priority in this area. In this study, we considered all
new cases of invasive breast cancer diagnosed in the Province of Modena, Italy, between 1997 and 2007, registered by the
Modena Cancer Registry. The principal endpoint of this study was relapse-free survival (RFS). A set of 11 clinic and
pathological parameters was investigated. After a median follow-up of 73 months, 494 relapses were recorded. Tumor size,
node status, grading, HER2 and estrogen receptor status were retained as independent factors in a multivariate analysis.
Using these variables, a prognostic model was devised to identify three groups at different risk. In the training sample, the
5-year RFS rates resulted 96.0%, 82.9% and 63.7% in patients at low, intermediate and high risk, respectively (p < 0.0001).
In the validation sample, the 5-year RFS was 96.2%, 85.4% and 66.9%, respectively. To conclude our study demonstrates that
a very simple prognostic index based on easily available clinical data may represent a useful tool for the identification of
patients at different risk of relapse and may be a notable device to predict who truly benefits from medical treatment.
The adoption of wide-scale mammographic screening for the
detection of breast cancer at an earlier phase of development
has resulted in an increasing number of cases being diagnosed
at a very early stage, together with a reduction in breast cancer
morbidity and mortality.1–3 However, the risk that screen-
detected cancer can lead to overdiagnosis in up to 24% of the
cases, has been recently suggested.4,5 Moreover, the introduc-
tion of the sentinel node procedure6–8 has led to an increase in
the detection rate of small lymph node metastases, due to
more accurate pathological assessment that include step sec-
tioning9,10 and immunohistochemistry.11 Finally, the new
drugs and an enhanced tuning of already existing therapeutic
approaches have contributed to a better disease control.
Consequently, a thorough search for more sensitive prog-
nostic factors, able to help clinicians offer appropriate adju-
vant therapy after surgery, balancing the beneﬁts of the pre-
vention of recurrence and the risks related with unnecessary
treatment, has become a priority in this area.
In the past, the recognition of prognostic factors was
based on the retrospective analysis of archive data and results
were limited by patient selection criteria, missing data, no
inclusion of more recently reported parameters and outdated
adjuvant therapies. Finally, although overall survival (OS)
should be the optimal endpoint, in a disease with an increas-
ing scarcity of events, it appears unrealistic and requires a
very long follow-up period.
For all these reasons, we collected an exhaustive set of
clinical, laboratory, pathological and therapeutic information
for all cases of breast cancer diagnosed in the Province of
Modena, Northern Italy, with the aim of identifying appro-
priate factors able to better deﬁne the disease prognosis in
terms of relapse-free survival (RFS).
Here we present the results of this study, which involved
4,970 new cases of operable breast cancer, registered between
1997 and 2007 and followed up to the year 2009.
Material and Methods
The Modena Cancer Registry collects data concerning incident
cases of all malignant tumors in the province of Modena (Italy).
In this study, we considered all new cases of invasive breast
cancer (ICD03 site code C50.0–C50.9 and behavior code/3)12
diagnosed between 1997 and 2007 with the last follow-up
updated to December 31, 2009. We excluded patients with met-
astatic disease and those treated with neo-adjuvant therapy.
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Statistical analysis
The principal endpoint of this study was RFS, deﬁned as the
time from the date of diagnosis to date of relapse of the pri-
mary breast cancer, or date of last follow-up for uncensored
cases. Local and distant relapses were considered as recur-
rences. RFS was estimated using the Kaplan–Meier method.13
Relative survival was calculated according to Ederer
method.14 We investigated 11 parameters dichotomized as
follows: age <70 vs. 70 years, tumor size 20 vs. >20 mm,
nodal status (deﬁned by the ratio of the percentage of posi-
tive nodes to total analyzed nodes) <10 vs. 10%, Ki67 pro-
liferative activity <20 vs. 20%, expression of estrogen recep-
tors (ER) 70 vs. <70%, expression of progesterone
receptors (PgR) 40 vs. <40%, presence or absence of associ-
ated ductal carcinoma in situ (DCIS), tumor grading (3 vs.
1–2), presence of angioinvasion, presence of multifocality,
and positivity to the human epidermal growth factor receptor
2 (HER2). The cut-off values for age, tumor size, nodal sta-
tus, Ki67, ER and PgR were chosen subdividing the patients
distribution in quartiles for explorative analysis and then and
identifying upper or lower quartiles or merging two neigh-
bors quartiles according to covariates. The age was dichotom-
ized at 70-year old for considering the elderly patients in the
upper quartile. The cut-off <20 mm in tumor size corre-
sponded to status T1 and represented the lower quartile
whereas the proliferative activity cut-off was predeﬁned at
Ki67 proliferation index of 20% (since the third upper
quartile corresponding to a high positively stained tumor
cells, 25%, falls close the cut-point reported in literature).
The covariate nodal status was grouped for any increased of
the ratio of 5% and the ratio >10% represented the upper
quartile. Estrogen receptor expression <70% represented the
lower quartile cut-off. The PgR expression cut-off corre-
sponded to the lower merged quartiles or median (<40%).
Grading III represented the upper quartile for grading score
compared to grading I-II put together.
Angioinvasion, DCIS associated, multifocality and HER2
overexpression were considered in a categorical way.
Angioinvasion was considered as little cluster of neoplastic
cells (5) inside the vessels by hematoxylin–eosin. Angioin-
vasion in peritumoral tissue was conﬁrmed by CD31 immu-
nostaining. The scoring of HER-2 by IHC was evaluated
semiquantitatively according to the following categories: 0, no
membrane staining; 1þ, partial membrane staining in >10%
of tumor cells; 2þ, weak complete staining in >10% of
tumor cells; 3þ, complete staining of the membrane in
>10% of tumor cells. The HER2/neu gene status was scored
as the ratio between HER-2 red signals and CEP17 green sig-
nals. A HER-2/CEP17 ratio >2 was interpreted as positive for
gene ampliﬁcation.15
The database was split into a training sample and a test
sample by residence in the health districts of the province of
Modena (training sample: district of Modena, Carpi and
Pavullo, N ¼ 2,296, 68%; test sample: districts of Mirandola,
Castelfranco Emilia and Vignola, N ¼ 1,099, 32%). The train-
ing sample was used to develop and validate the model, iden-
tifying the most appropriate score and the test sample was
excluded from the original database, ‘‘frozen’’ and used for
external validation. Univariate and multivariate analysis were
performed by means of Cox proportional hazard (PH)
regression.16
The Stata 8.2/SE package (StataCorp, College Station, TX)
was used for all statistical analysis. All P values were two
sided.
Results
Patient characteristics
Between 1997 and 2007, there were 6,131 new cases of inva-
sive breast cancer in the province of Modena. Excluding 781
patients because of lacking of status, metastatic disease or
neoadjuvant treatment before surgery, 5,350 cases were con-
sidered eligible for the purposes of the study. Finally, after
further exclusion of 377 cases, mainly due to lack of data, the
cohort considered for the analysis was composed of 4,970
women initially treated with radical tumor resection.
The main characteristics of the 4,970 eligible cases
included in the analysis are summarized in Table 1. As
regards the diagnostic modality, 1,641 tumors (33%) were
screen-detected. Mean age at diagnosis was 61 years (range,
26–95 years). Median tumor size was 15 mm (range, 1–46
mm), with most cases (2,164, 44%) falling in the T1c cate-
gory. Nodal status was available in 4,723 cases. In 247 cases,
axillary dissection or sentinel node biopsy was spared because
of the advanced age of the patients (72% of them were 70
years). Among 97 patients aged less than 70 years, 45 had a
tumor size 1 cm, whereas for 52 cases there was no clear
reason for lacking of nodal status information.
After a median follow-up of 73 months (range, 1–155),
and follow-up completeness of 88% (19), 494 relapses (9.9%)
were recorded, including 126 local (26%) and 368 distant
(74%) relapses. The average relapse rate was 16.4 (95% CI,
15.0–17.9) per 1,000 person-years; peak recurrence (21.6,
What’s new?
Mammography helps catch breast tumors while they are still treatable. Identifying more sensitive prognostic factors that
could be used during the course of treatment would help clinicians prevent recurrence and avoid unnecessary therapies. In
this paper, the authors collected clinical, laboratory, pathological, and therapeutic information on almost 5,000 cases of
operable breast cancer to find out which factors predicted successful recovery. They developed a prognostic index based on
five variables that can help clinicians determine whether a patient’s disease is likely to be helped by a particular drug,
making it worth the toxic side effects.
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95% CI, 17.6–26.5 per 1,000 person-years) was observed
between the second and third year after diagnosis of primary
breast cancer.
The 5- and 10-year RFS rates were 91.3% (95% CI, 90.4–
92.1%) and 85.4% (95% CI, 83.9–86.7%), respectively. The
outcome improved through the study period, with the 4-year
RFS 92% for cases diagnosed in the period 1997–2001 and
95% for those diagnosed in the years 2005–2007 (p ¼ 0.005).
At the same intervals, 5- and 10-year OS rates were 88.2
(95% CI, 87.2–89.1%) and 75.5% (95% CI, 73.7–77.1%),
respectively. Indeed the relative survival of the general popu-
lation after 5 and 10 years were 95.5% (95% CI, 94.4–96.5%)
and 91.5% (95% CI, 89.8–93.2%), respectively.
Prognostic model development
In univariate analysis, all 11 investigated variables had a stat-
istically signiﬁcant impact; thus further analyses were per-
formed in the group of 3,395 cases (68%) with a complete set
of data. The ﬁnal study sample of 3,395 cases was then split
into one training and one test sample. In the training sample,
a total of 206 events were observed, corresponding to an
event/variable ratio of 19:1, which represents a satisfactory
ratio for carrying out the multivariate analysis and avoiding
the problem of overﬁtting the model.17
As far as adjuvant therapy is concerned, 2,878 patients
(85%) were treated with systemic approach (chemotherapy
and/or hormone therapy plus or minus radiotherapy) whereas
517 (15%) received solely surgical treatment with or without
radiotherapy. Details on adjuvant therapy are given in Table 2.
The model was built by means of a bootstrap screening
with a backward elimination over the training sample. These
procedures were performed by means of a multivariate Cox
proportional hazard model with a selection guide of p ¼
0.10. The performance of the selected model was assessed by
the error rate (1-c Harrell) in an out-of bootstrap sample
that was used like a test data set. The procedure was repeated
1,000 times.18 Since the model gave the lowest error with ﬁve
or six covariates, we choose the ﬁve covariates more fre-
quently included, i.e., tumor size (100%), node status (99%),
grading (97%), HER2 status (85%) and estrogen receptor sta-
tus (64%). The subsequent covariates, angioinvasion (38%),
association with DCIS (37%), proliferative activity (31%),
progesterone receptor (30%), multifocality (13%) and age
(8%) were excluded from the multivariate analysis since had
a low frequency and high rate of error. At the end of this
process, a simple risk score was obtained using the ﬁve varia-
bles retained in the ﬁnal model (Table 3). A score was attrib-
uted to each variable according to its relative weight, derived
from the z-Wald values found in the Cox PH model, which
attributed nodal status and tumor size a weight double that
of tumor grading, estrogen receptor status and HER2 status.
The score ranged from 0 to 7 and the patients were stratiﬁed
according to the following three risk groups: score 0–2
(72.4%), low risk; score 3 and 4 (19.0%), intermediate risk
and score 5–7 (8.6%), high risk.
Table 1. Characteristics of the patients recorded in Modena Cancer
registry between 1997 and 2007
Variable N Mean Median Range
Age (year) 4,970 61 61 22–96
Tumor size (mm) 4,895 17 15 1–90
Estrogen receptor (%) 4,605 68 85 0–100
Progesterone receptor (%) 4,593 41 35 0–100
Proliferative activity (%) 4,517 18 13 0–100
Nodal status (%) 4,930 8 0 0–100
N %
Grading 4,646
1 736 16
2 2,060 44
3 1,850 40
N 4,970
NX 247 5
N0 3,126 63
N1 1,067 21
N2 304 6
N3 226 5
T 4,950
T1mic-T1b 1,497 30
T1c 2,164 44
T2 1,289 26
DCIS associated 4,970
No 2,321 47
Yes 2,649 53
Sentinel node 4,970
No 3,187 64
Yes 1,783 36
Axillary node dissection 4,970
No 1,472 30
Yes 3,498 70
Multifocality 4,970
No 4,356 88
Yes 614 12
Angioinvasion 4,970
No 4,338 87
Yes 632 13
HER2 3,610
Negative 3,131 87
Positive 479 13
Year of diagnosis
1997–2001 2,178 44
2002–2004 1,442 29
2005–2007 1,350 27
N, nodes; T, tumor; DCIS, ductal carcinoma in situ; HER2: epidermal
growth factor receptor 2.
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In the training sample (N ¼ 2,296), the 5-year RFS rates
were 96.0% (95% CI, 94.8–96.9%), 82.9% (95% CI, 78.6–
86.5%) and 63.7% (95% CI, 55.2–70.9%) in patients at low,
intermediate and high risk, respectively (p < 0.0001, c-Har-
rell 0.734); and the 10-year RFS rates were 92.1% (95% CI,
88.0–94.9%), 71.5% (95% CI, 60.9–79.6%) and 50.9% (95%
CI, 38.7–61.8%) for each risk category, respectively (p <
0.0001) (Fig. 1a). Furthermore, the hazard ratio between
score 3 and 4 and 0/2 was 4.57 (95% CI, 3.28–6.36, p <
0.001) and between score 5/7 and 3–4 was 2.36 (95% CI,
1.69–3.30, p < 0.001). The 5-year OS rates were 92.5%,
81.0% and 64.8% and the 5-year relative survival rates were
99.1%, 90.0% and 72.5% for patients at low, intermediate and
high risk, respectively (p < 0.0001).
External validation
Patient characteristics of the test sample were similar to those
of the study sample for all variables except high tumor grade
(46 vs. 40) and large tumor size (35 vs. 30). The RFS at 5 and
10 years (90.8% and 84.5%) compared favorably with that
observed in the study sample (90.9% and 85.0%) (p ¼ 0.567).
Seven hundred and forty patients (67%) had a score of
0–2, 244 (22%), a score of 3–4 and 115 patients (11%) had a
score of 5–7. The corresponding RFS at 5 years by score 0–2,
3–4 and 5/7 were 96.2% (95% CI, 94.4–97.5%), 85.4% (95%
CI, 79.1–89.8%); and 66.9% (95% CI, 56.1–75.6%), respec-
tively; and RFS at 10 years for scores 0–2, 3–4 and 5–7 were
92.6% (95% CI, 88.2–95.4%), 77.0% (95% CI, 66.3–84.6%)
and 40.7% (95% CI, 16.6–63.7%), respectively (Fig. 1b).
Patients who only received surgical treatment plus or
minus radiotherapy had a median age of 68 years compared
to 59 years of patients treated with systemic therapy (p <
0.001), were more likely affected with T2 tumor size (36% vs.
31%; p ¼ 0.018) and had more frequently ER expression
<70% (32% vs. 24%; p < 0.001). On the other hand, patients
locally treated had less nodal status 10% than those with
systemic therapy (14% vs. 19%, p ¼ 0.006). Finally, no statis-
tically signiﬁcant difference in frequency distribution for all
score levels between patients with and without systemic ther-
apy was seen (p ¼ 0.200).
The unstratiﬁed hazard ratio of surgery 6 RT vs. surgery
plus systemic therapy on RFS was 1.05 (95% CI, 0.77–1.43,
p ¼ 0.774). The HR of surgery 6 RT vs. surgery plus sys-
temic therapy by score 0–2, 3–4 and 5/7 were 1.23 (95% CI,
0.73–2.07; p ¼ 0.444), 0.99 (95% CI, 0.58–1.70; p ¼ 0.986)
and 0.83 (95% CI, 0.47–1.47; p ¼ 0.529), respectively (Fig. 2).
Moreover, the difference in D statistic between the test
and training samples (over 250 bootstrap resample) was
0.02, indicating good reproducibility (Table 4). The hazard
ratio between score 3 and 4 and 0–2 was 3.58 (95% CI, 2.18–
5.90, p < 0.001) and between score 5 and 7 and 3–4, it was
2.92 (95% CI, 1.82–4.68, p < 0.001).
Discussion
By using data from a population-based cancer registry, which
also allowed us to collect information on treatment modal-
ities and outcome of patients diagnosed with breast cancer in
the province of Modena (Italy), we have developed a prog-
nostic index based on the ﬁve most appropriate variables
such as, tumor size, node status, grading, HER2 status and
estrogen receptor status, previously selected according to a
bootstrap screening.
Although the adoption of categorical variables in modeling
procedures has been heavy criticized by statisticians19 our results
compare favorably with other scores that allow the probability
of recurrence from breast cancer to be accurately estimated and
include the Nottingham Prognostic Index (NPI),20 Adjuvant!
Online,21 Mammaprint22 or Oncotype Dx RSs.23
In particular, our study conﬁrms the validity of the NPI,
developed in 1982, that divides operable patients with breast
cancer into good, moderate and poor prognostic groups with
15-year survival of 80%, 42% and 13%, respectively.24 In fact,
our results, conﬁrmed in the test sample, showed a 10-year
RFS rates of 92.1% (95% CI, 88.0–94.9%), 71.5% (95% CI,
60.9–79.6%) and 50.9% (95% CI, 38.7–61.8%) for each risk
category, respectively (p < 0.0001). The paradox of RFS
Table 2. Distribution of therapies in the 3,395 patients included in
the building and validation model recorded in the Modena Cancer
Registry between 1997 and 2007 and modality of diagnosis
Therapy N %
Chemotherapy 1,275
CPM 493 39
ANTHRA 660 51
ANTHRA 6 TAX 117 9
Not assessed 5 <1
Radiotherapy 3,395
No 1,268 37
Yes 2,127 63
Hormone therapy 3,395
No 840 25
Yes 2,555 75
Therapy combination 3,395
CHT þ RT þ HT 678 20
CHT þ RT 224 7
CHT þ HT 274 8
RT þ HT 1,087 32
CHT 99 3
HT 516 15
Surgery 6 RT 517 15
Screen detected 3,395
No 2,183 64
Yes 1,212 36
CPM: regimens containing cyclophosphamide; ANTHRA: regimens
containing anthracycline; TAX: regimens containing taxanes; CHT:
generic chemotherapy; RT: radiotherapy; HT: hormone therapy. Note:
Because of rounding, percentages may not total 100.
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being better than OS can be attributed to the advanced age
of the investigated study population, in which a large propor-
tion of deaths in the general population were unrelated to
breast cancer and its treatment.
Recently, the addition of progesteron receptor and HER2
to NPI increases its 5-year prognostic accuracy.25
Although no biological material was disposable for com-
paring our model with a gene expression proﬁling system,
such as OncotypeDX, that uses a candidate-gene approach to
generate a quantitative recurrence score (RS) and deﬁnes
three risk categories of recurrence (low < 18, intermediate
between 19 and 31 and high S > 32) or MammaPrint,
Table 3. Association between the patient characteristics at diagnosis and RFS evaluated by means univariate and multivariate Cox
proportional hazard analysis in the training sample (N ¼ 3,395)
HR (95% CI) HR (95% CI)
Parameter % 10-years RFS% (SE) Univariate Multivariate z
Nodal status
<10% 82 89 (1.7) 1.0 1.0
10% 18 64(4.2) 4.33 (3.29–5.71) 2.86 (2.14–3.83) 7.1
Tumor size
20 mm 75 90 (1.7) 1.0 1.0
>20 mm 25 69 (4.0) 4.00 (3.05–5.27) 2.47 (1.84–3.31) 6.0
Grading
1–2 60 90 (2.4) 1.0 1.0
3 40 76 (2.5) 3.55 (2.65–4.75) 2.02 (1.42–2.69) 4.1
HER2
Negative 87 86 (1.8) 1.0 1.0
Positive 13 75 (3.5) 2.74 (2.01–3.72) 1.95 (1.42–2.69) 4.1
Estrogen receptor
70% 74 90 (1.2) 1.0 1.0
<70 % 26 77 (3.0) 2.28 (1.73–3.00) 1.54 (1.16–2.06) 2.9
Angioinvasion
No 87 87 (1.8) 1.0
Yes 13 69 (4.0) 3.22 (2.38–4.34)
DCIS associated
No 38 80 (3.1) 1.0
Yes 62 88 (1.4) 0.67 (0.51–0.88)
Proliferative activity
<20% 60 87 (2.4) 1.0
20% 40 82 (1.8) 2.53 (1.91–3.35)
Progesterone receptor
40% 53 86 (3.3) 1.0
<40% 47 82 (1.8) 1.82 (1.37–2.42)
Age
<70 72 88 (1.9) 1.0
70 28 83 (3.0) 1.48 (1.10–1.98)
Multifocality
No 87 85 (1.8) 1.0
Yes 13 84 (2.9) 1.29 (0.89–1.87)
Slope shrinkage 0.986
Corrected c-Harrell 0.765
HR: hazard ratio; CI: confidence intervals; HER2: epidermal growth factor receptor 2; DCIS: ductal carcinoma in situ. z ¼ z-statistic from Wald test;
slope shrinkage and corrected c-Harrell obtained over 250 bootstrap replications.
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developed with a supervised top-down approach, that meas-
ures the expression of 70 genes to categorize patients into
‘‘good’’ or ‘‘poor’’ risk groups, we can argue that our results
reﬂect data of a recent breast cancer gene signatures meta-
analysis where tumor size and nodal status, still retain an in-
dependent predictive value of distant relapse.26
An interesting point that emerges from this work is that
no differences were observed in RFS between patients who
Figure 1. RFS stratified according to prognostic score index in training (a) and test sample (b). Solid line: low-risk score (0/2); dashed line:
intermediate risk score (3–4); dotted line: high-risk score (5/7).
Figure 2. RFS stratified by treatments, according to the proposed prognostic score index, in the 3395 cases with complete data. Solid
lines: systemic therapy; dashed lines: surgical treatment 6 RT.
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received only surgery 6 radiotherapy compared to patients
treated with systemic therapy in the three risk categories.
Patients with advanced age were only locally treated probably
because of comorbidities. Despite a greater T size and lower
ER expression of patients treated by surgery plus or minus
RT compared to those undergone systemic therapy, no statis-
tically signiﬁcant differences in score appeared, probably due
to the fact that nodal status, which has a double weight in
the score assessment, was less frequently evidenced. Our
results suggests that elderly patients, although show a greater
tumor size than younger ones, probably have less capability
to metastasize lymph nodes. So we suggest that elderly people
could be spared for such therapies.
Furthermore, screen detected cancers are smaller sized, are
more likely to be grading I–II, with low proliferative activity
and displays an excellent outcome, thus questioning the need
for chemotherapy.27,28 Our data, derived from an area where
a signiﬁcant proportion of breast cancers were diagnosed
with active mammographic screening, indicate that the prog-
nostic categories as deﬁned using classic or genomic methods,
can overestimate the risk of recurrence and as a consequence
the risk of unnecessary adjuvant treatments is therefore
ampliﬁed.
Undoubtedly, our model could be improved by reworking
the T1 category as a dynamic ﬁling system as suggested by
Veronesi et al.29 However, we adopted the T1 cut-off to sepa-
rate small tumors from large ones, as obtained from our in-
ternal analysis on continuous variables.
As far as nodal status is concerned, we incorporated into
the model the nodal ratio, a new index that would appear to
be more accurate than pN classiﬁcation in predicting survival
after breast cancer and proposed as an alternative to pN stag-
ing. In a previous series of 82 patients, a nodal ratio >20%
was associated with local recurrence with a 10-year relapse of
28.7%.30 More recently, Vinh-Hung et al.8 showed that the
lymph node ratio predicts survival after breast cancer more
accurately than pN classiﬁcation and should be considered as
an alternative to pN staging, by dividing the patients into
low, intermediate and high risk with 20%, >20% to 65%
and >65%, respectively.
Regarding the importance of estrogen receptor status, it is
well known that there is a marginally statistically signiﬁcant
relationship between ER level (as a continuous variable) and
time to relapse (TTR), with lower levels being associated with
a shorter TTR.31 Estrogen expression dichotomization was
chosen according to Collins et al.32 which showed that
among 825 cases evaluated for ER expression, 660 (80%) had
positivity in 70% or more of the tumor cells. The Ki67 cut-
off 20%, was found corresponding to the upper quartile in
a previous paper published by Ahlin et al.33 before the intro-
duction of 2011 St. Gallen guidelines.
In conclusion, the model proposed here is a simple prog-
nostic index based on readily available clinical data and may
represent a promising new tool for the identiﬁcation of
patients with different risks of disease progression at a time
when a signiﬁcant number of cases are diagnosed through
active screening procedures. This is particularly relevant con-
sidering the increasing availability of new and very expensive
drugs that should be offered only if truly able to further
improve the chances of cure and thus justify treatment-
induced toxicity.
In the future, a comparison with gene expression proﬁling
systems (Mammaprint or Oncotype DX) could be desirable
to validate our prognostic model in a prospective study.
Table 4. Validation of the prognostic score on the test sample
Training sample N ¼ 2,296 Test sample N ¼ 1,099
N %
RFS (%)
10 years N %
RFS (%)
10 years
Score
Low (0/2) 1,662 72.4 92 740 67.3 93
Intermediate (3–4) 437 19.0 72 244 22.2 77
High (5/7) 197 8.6 51 115 10.5 41
Score HR 95% CI p HR 95% CI p
Intermediate
vs. Low
4.57 3.28–6.36 <0.001 3.58 2.18–5.90 <0.001
High vs.
Intermediate
2.36 1.69–3.30 <0.001 2.92 1.82–4.68 <0.001
High vs. Low 10.8 7.67–15.2 <0.001 10.5 6.47–16.9 <0.001
D Royston 1.67 (SE 0.12) 1.65 (SE 0.18)
D difference 0.02 (95% CI 0.44 to 0.40)
Shrinkage 0.982 (SE 0.101)
c-Harrell 0.734 (95% CI 0.702–0.767) 0.728 (95% CI 0.677–0.778)
CI: confidence intervals; D difference: (D test  D training) sample. D difference and 95% CI of c-Harrell
obtained over 250 bootstrap resample.
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